{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:02:59Z","timestamp":1792918979152,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31 DK138794-01A1"],"award-info":[{"award-number":["F31 DK138794-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","award":["International seed grant"],"award-info":[{"award-number":["International seed grant"]}],"id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K19585"],"award-info":[{"award-number":["25K19585"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.exphem.2026.105493","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:26:19Z","timestamp":1786749979000},"page":"105493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Unlocking the curative potential of gene transfer and editing for hematopoietic disorders"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8721-2430","authenticated-orcid":false,"given":"Kohei","family":"Shiroshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-204X","authenticated-orcid":false,"given":"Anne","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Malouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5320-3280","authenticated-orcid":false,"given":"Vu L.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-9753","authenticated-orcid":false,"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Naldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105493_bib0001","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2016.10.044","article-title":"CRISPR-based technologies for the manipulation of eukaryotic genomes","volume":"168","author":"Komor","year":"2017","journal-title":"Cell."},{"key":"10.1016\/j.exphem.2026.105493_bib0002","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.stem.2022.09.001","article-title":"Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells","volume":"29","author":"Ferrari","year":"2022","journal-title":"Cell Stem Cell."},{"key":"10.1016\/j.exphem.2026.105493_bib0003","first-page":"539","article-title":"Multiple transcripts of T-DNA detected in nopaline crown gall tumors","volume":"1","author":"Bevan","year":"1982","journal-title":"J Mol Appl Genet."},{"key":"10.1016\/j.exphem.2026.105493_bib0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00187570","article-title":"Liposome-mediated delivery of tobacco mosaic virus RNA into petunia protoplast: improved conditions for liposome-protoplast incubations","volume":"2","author":"Fraley","year":"1983","journal-title":"Plant Mol Biol."},{"key":"10.1016\/j.exphem.2026.105493_bib0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/j.1460-2075.1983.tb01532.x","article-title":"Chimeric genes as dominant selectable markers in plant cells","volume":"2","author":"Herrera-Estrella","year":"1983","journal-title":"Embo J."},{"key":"10.1016\/j.exphem.2026.105493_bib0006","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/310476a0","article-title":"Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse","volume":"310","author":"Williams","year":"1984","journal-title":"Nature."},{"key":"10.1016\/j.exphem.2026.105493_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omtm.2017.10.001","article-title":"Interactions between retroviruses and the host cell genome","volume":"8","author":"Poletti","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1016\/j.exphem.2026.105493_bib0008","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1073\/pnas.81.20.6466","article-title":"Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells","volume":"81","author":"Hermonat","year":"1984","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.exphem.2026.105493_bib0009","first-page":"3251","article-title":"Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells","volume":"5","author":"Tratschin","year":"1985","journal-title":"Mol Cell Biol."},{"key":"10.1016\/j.exphem.2026.105493_bib0010","first-page":"2072","article-title":"A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase","volume":"4","author":"Tratschin","year":"1984","journal-title":"Mol Cell Biol."},{"key":"10.1016\/j.exphem.2026.105493_bib0011","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science."},{"key":"10.1016\/j.exphem.2026.105493_bib0012","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41573-019-0020-9","article-title":"Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges","volume":"18","author":"Cavazzana","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.exphem.2026.105493_bib0013","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science."},{"key":"10.1016\/j.exphem.2026.105493_bib0014","doi-asserted-by":"crossref","first-page":"227ra233","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2013long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0015","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/1873-3468.13668","article-title":"Adenovirus vectors in hematopoietic stem cell genome editing","volume":"593","author":"Li","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.exphem.2026.105493_bib0016","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41591-023-02789-4","article-title":"Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency","volume":"30","author":"Migliavacca","year":"2024","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0017","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0018","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105493_bib0019","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2026.105493_bib0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0021","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2026.105493_bib0022","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.stem.2018.10.008","article-title":"Cyclosporine H overcomes innate immune restrictions to improve lentiviral transduction and gene editing in human hematopoietic stem cells","volume":"23","author":"Petrillo","year":"2018","journal-title":"Cell Stem Cell."},{"key":"10.1016\/j.exphem.2026.105493_bib0023","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","article-title":"Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response","volume":"24","author":"Schiroli","year":"2019","journal-title":"Cell Stem Cell."},{"key":"10.1016\/j.exphem.2026.105493_bib0024","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213817","article-title":"Metachromatic leukodystrophy: new therapy advancements and emerging research directions","volume":"105","author":"Asbreuk","year":"2025","journal-title":"Neurology."},{"key":"10.1016\/j.exphem.2026.105493_bib0025","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1126\/science.290.5497.1775","article-title":"From marrow to brain: expression of neuronal phenotypes in adult mice","volume":"290","author":"Brazelton","year":"2000","journal-title":"Science."},{"key":"10.1016\/j.exphem.2026.105493_bib0026","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1073\/pnas.0337659100","article-title":"Contribution of transplanted bone marrow cells to Purkinje neurons in human adult brains","volume":"100","author":"Weimann","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.exphem.2026.105493_bib0027","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1172\/JCI200419205","article-title":"Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells","volume":"113","author":"Biffi","year":"2004","journal-title":"J Clin Invest."},{"key":"10.1016\/j.exphem.2026.105493_bib0028","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science."},{"key":"10.1016\/j.exphem.2026.105493_bib0029","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-024-08250-x","article-title":"Long-term lineage commitment in haematopoietic stem cell gene therapy","volume":"636","author":"Calabria","year":"2024","journal-title":"Nature."},{"key":"10.1016\/j.exphem.2026.105493_bib0030","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41586-024-08128-y","article-title":"Clonal dynamics after allogeneic haematopoietic cell transplantation","volume":"635","author":"Spencer Chapman","year":"2024","journal-title":"Nature."},{"key":"10.1016\/j.exphem.2026.105493_bib0031","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41587-020-0551-y","article-title":"Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking","volume":"38","author":"Ferrari","year":"2020","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.exphem.2026.105493_bib0032","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.2022019333","article-title":"Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells","volume":"142","author":"Vavassori","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105493_bib0033","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114188","article-title":"Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4(+) T-cells for the treatment of Hyper IgM1","volume":"42","author":"Canarutto","year":"2023","journal-title":"Embo j."},{"key":"10.1016\/j.exphem.2026.105493_bib0034","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat Commun."},{"key":"10.1016\/j.exphem.2026.105493_bib0035","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0036","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymthe.2024.12.028","article-title":"Balancing efficacy and safety in lentiviral vector-mediated hematopoietic stem cell gene therapy","volume":"33","author":"Montini","year":"2025","journal-title":"Mol Ther."},{"key":"10.1016\/j.exphem.2026.105493_bib0037","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2601608","article-title":"Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery","volume":"394","author":"Ahrens-Nicklas","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105493_bib0038","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41587-024-02171-w","article-title":"Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors","volume":"43","author":"Suchy","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2026.105493_bib0039","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12859-017-1937-9","article-title":"VISPA2: a scalable pipeline for high-throughput identification and annotation of vector integration sites","volume":"18","author":"Spinozzi","year":"2017","journal-title":"BMC Bioinformatics."},{"key":"10.1016\/j.exphem.2026.105493_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.omta.2025.201659","article-title":"RAAVioli: A comprehensive approach to characterizing AAV vector integrations and rearrangements","volume":"34","author":"Cipriani","year":"2026","journal-title":"Mol Ther Adv."},{"key":"10.1016\/j.exphem.2026.105493_bib0041","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41596-020-00431-y","article-title":"Tools for experimental and computational analyses of off-target editing by programmable nucleases","volume":"16","author":"Bao","year":"2021","journal-title":"Nat Protoc."},{"key":"10.1016\/j.exphem.2026.105493_bib0042","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.exphem.2026.105493_bib0043","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.aav9023","article-title":"Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq","volume":"364","author":"Wienert","year":"2019","journal-title":"Science."},{"key":"10.1016\/j.exphem.2026.105493_bib0044","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat Methods."},{"key":"10.1016\/j.exphem.2026.105493_bib0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nmeth.3284","article-title":"Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells","volume":"12","author":"Kim","year":"2015","journal-title":"Nat Methods."},{"key":"10.1016\/j.exphem.2026.105493_bib0046","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41587-020-0555-7","article-title":"CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity","volume":"38","author":"Lazzarotto","year":"2020","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.exphem.2026.105493_bib0047","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"Brinkman","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.exphem.2026.105493_bib0048","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/crispr.2021.0113","article-title":"Inference of CRISPR Edits from Sanger Trace Data","volume":"5","author":"Conant","year":"2022","journal-title":"Crispr j."},{"key":"10.1016\/j.exphem.2026.105493_bib0049","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","article-title":"A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells","volume":"24","author":"Vakulskas","year":"2018","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.exphem.2026.105493_bib0051","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","article-title":"Genotoxic effects of base and prime editing in human hematopoietic stem cells","volume":"42","author":"Fiumara","year":"2024","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.exphem.2026.105493_bib0052","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","article-title":"Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq","volume":"28","author":"Turchiano","year":"2021","journal-title":"Cell Stem Cell."},{"key":"10.1016\/j.exphem.2026.105493_bib0053","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag318","article-title":"DNA-PKcs inhibitor AZD7648 reveals sgRNA cross-contaminants and enhanced sensitivity of genome engineering off-target activity in HSPCs","volume":"54","author":"White","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.exphem.2026.105493_bib0054","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1038\/s41467-025-65182-4","article-title":"Unveiling the cut-and-repair cycle of designer nucleases in human stem and T cells via CLEAR-time dPCR","volume":"16","author":"White","year":"2025","journal-title":"Nat Commun."},{"key":"10.1016\/j.exphem.2026.105493_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.omta.2026.201816","article-title":"In-Depth Characterization of Stem Cell Potency and Genotoxicity for Clinical-Scale Ex Vivo CRISPR\/Cas9 Gene Editing","author":"Naseem","year":"2026","journal-title":"Molecular Therapy Advances."},{"key":"10.1016\/j.exphem.2026.105493_bib0056","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ymthe.2024.03.037","article-title":"CRISPR-Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia","volume":"32","author":"Nasri","year":"2024","journal-title":"Mol Ther."},{"key":"10.1016\/j.exphem.2026.105493_bib0057","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231235","article-title":"Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy","volume":"220","author":"Marone","year":"2023","journal-title":"J Exp Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0058","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ymthe.2021.06.016","article-title":"Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques","volume":"30","author":"AlJanahi","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2026.105493_bib0059","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.stem.2026.04.014","article-title":"Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation","volume":"33","author":"Lei","year":"2026","journal-title":"Cell Stem Cell."},{"key":"10.1016\/j.exphem.2026.105493_bib0060","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1038\/s41587-024-02488-6","article-title":"Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations","volume":"43","author":"Cullot","year":"2025","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.exphem.2026.105493_bib0061","article-title":"A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells","volume":"5","author":"Della Volpe","year":"2024","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0062","article-title":"Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9\/AAV6-mediated gene editing in hematopoietic stem cells","volume":"6","author":"Conti","year":"2025","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0063","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-026-03142-z","article-title":"Selection of human hematopoietic stem cells bearing the intended functional edit by transient AND-gate reporters","author":"Canarutto","year":"2026","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.exphem.2026.105493_bib0064","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41591-023-02636-6","article-title":"Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease","volume":"29","author":"Spencer Chapman","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2026.105493_bib0065","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1038\/s41596-021-00529-x","article-title":"BAR-Seq clonal tracking of gene-edited cells","volume":"16","author":"Ferrari","year":"2021","journal-title":"Nat Protoc."},{"key":"10.1016\/j.exphem.2026.105493_bib0066","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41467-020-20792-y","article-title":"The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat Commun."},{"key":"10.1016\/j.exphem.2026.105493_bib0067","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-024-07066-z","article-title":"Deciphering cell states and genealogies of human haematopoiesis","volume":"627","author":"Weng","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2026.105493_bib0068","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s41587-022-01210-8","article-title":"Mitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations","volume":"40","author":"Miller","year":"2022","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.exphem.2026.105493_bib0069","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41586-025-09041-8","article-title":"Clonal tracing with somatic epimutations reveals dynamics of blood ageing","volume":"643","author":"Scherer","year":"2025","journal-title":"Nature."},{"key":"10.1016\/j.exphem.2026.105493_bib0070","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1056\/NEJMoa1013579","article-title":"A hemoglobin variant associated with neonatal cyanosis and anemia","volume":"364","author":"Crowley","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0071","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM198407053110102","article-title":"Influence of sickle hemoglobinopathies on growth and development","volume":"311","author":"Platt","year":"1984","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0072","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.3390\/jcm9113782","article-title":"Fetal hemoglobin in sickle hemoglobinopathies: high HbF genotypes and phenotypes","volume":"9","author":"Steinberg","year":"2020","journal-title":"J Clin Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0073","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/313325a0","article-title":"A point mutation in the A gamma-globin gene promoter in Greek hereditary persistence of fetal haemoglobin","volume":"313","author":"Collins","year":"1985","journal-title":"Nature."},{"key":"10.1016\/j.exphem.2026.105493_bib0074","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00291702","article-title":"A frequent A gamma-hereditary persistence of fetal hemoglobin in northern Sardinia: its molecular basis and hematologic phenotype in heterozygotes and compound heterozygotes with beta-thalassemia","volume":"79","author":"Ottolenghi","year":"1988","journal-title":"Hum Genet."},{"key":"10.1016\/j.exphem.2026.105493_bib0075","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood.V68.6.1389.1389","article-title":"The British form of hereditary persistence of fetal hemoglobin results from a single base mutation adjacent to an S1 hypersensitive site 5\u2032 to the A gamma globin gene","volume":"68","author":"Tate","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105493_bib0076","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ajh.2830420209","article-title":"G gamma A gamma (beta+) hereditary persistence of fetal hemoglobin: the G gamma -158 C\u2013>T mutation in cis to the -175 T\u2013>C mutation of the A gamma-globin gene results in increased G gamma-globin synthesis","volume":"42","author":"Coleman","year":"1993","journal-title":"Am J Hematol."},{"key":"10.1016\/j.exphem.2026.105493_bib0077","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2141.1975.tb01807.x","article-title":"Globin chain synthesis in the greek type (A gamma) of hereditary persisitence of fetal haemoglobin","volume":"29","author":"Sofroniadou","year":"1975","journal-title":"Br J Haematol."},{"key":"10.1016\/j.exphem.2026.105493_bib0078","doi-asserted-by":"crossref","first-page":"10635","DOI":"10.1093\/nar\/16.22.10635","article-title":"Distal CCAAT box deletion in the A gamma globin gene of two black adolescents with elevated fetal A gamma globin","volume":"16","author":"Gilman","year":"1988","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.exphem.2026.105493_bib0079","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.tig.2022.07.003","article-title":"Effective therapies for sickle cell disease: are we there yet?","volume":"38","author":"Crossley","year":"2022","journal-title":"Trends Genet."},{"key":"10.1016\/j.exphem.2026.105493_bib0080","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level","volume":"342","author":"Bauer","year":"2013","journal-title":"Science."},{"key":"10.1016\/j.exphem.2026.105493_bib0081","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0082","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm.4170","article-title":"A genome-editing strategy to treat \u03b2-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition","volume":"22","author":"Traxler","year":"2016","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0083","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0084","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","article-title":"CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric \u03b2(0)\/\u03b2(0) transfusion-dependent \u03b2-thalassemia","volume":"28","author":"Fu","year":"2022","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0085","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMoa2415550","article-title":"CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat sickle cell disease","volume":"394","author":"Hanna","year":"2026","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0086","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2501277","article-title":"CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat \u03b2-thalassemia","volume":"394","author":"Frangoul","year":"2026","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0087","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/bloodadvances.2024015574","article-title":"BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice","volume":"9","author":"Jang","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.exphem.2026.105493_bib0088","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/bloodadvances.2024014040","article-title":"Nonclinical evaluation of HBG1\/2 and BCL11A as genome-editing targets for the treatment of \u03b2-hemoglobinopathies","volume":"9","author":"Janoudi","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.exphem.2026.105493_bib0089","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene Autotemcel for Transfusion-Dependent \u03b2-Thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0090","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2026.105493_bib0091","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tig.2013.10.001","article-title":"Ldb1 complexes: the new master regulators of erythroid gene transcription","volume":"30","author":"Love","year":"2014","journal-title":"Trends Genet."},{"key":"10.1016\/j.exphem.2026.105493_bib0092","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2504835","article-title":"Base editing of HBG1 and HBG2 promoters for sickle cell disease","volume":"394","author":"Gupta","year":"2026","journal-title":"N Engl J Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0093","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41586-026-10342-9","article-title":"Clinical application of base editing for treating \u03b2-thalassaemia","volume":"653","author":"Lai","year":"2026","journal-title":"Nature."},{"key":"10.1016\/j.exphem.2026.105493_bib0094","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/MOH.0000000000000807","article-title":"Hematopoietic stem cell collection for sickle cell disease gene therapy","volume":"31","author":"Leonard","year":"2024","journal-title":"Curr Opin Hematol."},{"key":"10.1016\/j.exphem.2026.105493_bib0095","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","article-title":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial","volume":"29","author":"Crees","year":"2023","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0096","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41587-024-02360-7","article-title":"Long-term engrafting multilineage hematopoietic cells differentiated from human induced pluripotent stem cells","volume":"43","author":"Ng","year":"2025","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.exphem.2026.105493_bib0097","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0140-6736(09)60945-4","article-title":"Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1\/2 study","volume":"374","author":"Straathof","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.exphem.2026.105493_bib0098","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41591-025-03817-1","article-title":"Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial","volume":"31","author":"Agarwal","year":"2025","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0099","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1182\/blood.2024024636","article-title":"cMPL-based purification and depletion of human hematopoietic stem cells: implications for pretransplant conditioning","volume":"145","author":"Araki","year":"2025","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105493_bib0100","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.cell.2022.04.039","article-title":"Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells","volume":"185","author":"Omer-Javed","year":"2022","journal-title":"Cell."},{"key":"10.1016\/j.exphem.2026.105493_bib0101","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","article-title":"Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India","volume":"30","author":"Cornetta","year":"2022","journal-title":"Mol Ther."},{"key":"10.1016\/j.exphem.2026.105493_bib0102","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41576-025-00827-0","article-title":"Challenges and solutions to the sustainability of gene and cell therapies","volume":"26","author":"Scotti","year":"2025","journal-title":"Nat Rev Genet."},{"key":"10.1016\/j.exphem.2026.105493_bib0103","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-024-03035-1","article-title":"Enhancing pediatric access to cell and gene therapies","volume":"30","author":"Mackall","year":"2024","journal-title":"Nat Med."},{"key":"10.1016\/j.exphem.2026.105493_bib0104","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41591-022-01934-9","article-title":"Ensuring a future for gene therapy for rare diseases","volume":"28","author":"Aiuti","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2026.105493_bib0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2025.09.031","article-title":"Nonclinical evaluation of renizgamglogene autogedtemcel for SCD and TDT","volume":"34","author":"Marco","year":"2026","journal-title":"Mol Ther."},{"key":"10.1016\/j.exphem.2026.105493_bib0106","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2025.12.030","article-title":"A new advance in therapeutic induction of fetal hemoglobin on an uncertain road to durable access","volume":"34","author":"Manwani","year":"2026","journal-title":"Mol Ther."},{"key":"10.1016\/j.exphem.2026.105493_bib0107","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1016\/j.ymthe.2025.09.049","article-title":"Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases","volume":"33","author":"Barrett","year":"2025","journal-title":"Mol Ther."},{"key":"10.1016\/j.exphem.2026.105493_bib0108","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science."},{"key":"10.1016\/j.exphem.2026.105493_bib0109","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41587-024-02470-2","article-title":"Lipid nanoparticle-mediated mRNA delivery to CD34(+) cells in rhesus monkeys","volume":"43","author":"Kim","year":"2025","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.exphem.2026.105493_bib0110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell."},{"key":"10.1016\/j.exphem.2026.105493_bib0111","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-025-02915-2","article-title":"In vivo gene editing of human hematopoietic stem and progenitor cells using envelope-engineered virus-like particles","author":"Botchkarev","year":"2025","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.exphem.2026.105493_bib0112","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41586-025-09070-3","article-title":"In vivo haemopoietic stem cell gene therapy enabled by postnatal trafficking","volume":"643","author":"Milani","year":"2025","journal-title":"Nature."},{"key":"10.1016\/j.exphem.2026.105493_bib0113","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41551-025-01480-y","article-title":"In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery","volume":"10","author":"Xu","year":"2025","journal-title":"Nat Biomed Eng."},{"key":"10.1016\/j.exphem.2026.105493_bib0114","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162939","article-title":"In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies","volume":"7","author":"Li","year":"2022","journal-title":"JCI Insight."},{"key":"10.1016\/j.exphem.2026.105493_bib0115","first-page":"2085","article-title":"In vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105493_bib0116","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N Engl J Med."}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26001268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26001268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:22:58Z","timestamp":1791566578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26001268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":116,"alternative-id":["S0301472X26001268"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105493","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking the curative potential of gene transfer and editing for hematopoietic disorders","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Experimental Hematology.","name":"copyright","label":"Copyright"}],"article-number":"105493"}}